Organization (Industry)
ABBVIE INC.
ClinicalTrials.gov lists ABBVIE INC. as lead sponsor of 1,399 trials, counting the companies grouped under it. ABBVIE INC. itself has 715 active development programs and 156 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 78 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 91 in 2026 and about 95 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo AbbVie Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ABBVIE INC. and 17 companies grouped under it: 1,399 lead-sponsored trials (1,187 its own, 212 in the grouped companies) and 29 legal-entity registrations (19 its own, 10 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (17)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Repros Therapeutics (United States) | 58 | 1 |
| Warner Chilcott | 58 | 0 |
| Zeltiq Aesthetics | 39 | 0 |
| Cerevel Therapeutics (United States) | 22 | 2 |
| Tobira Therapeutics, Inc. | 12 | 0 |
Showing 5 of 17 member companies.
Disease areas (314)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis C | 130 |
| Lymphoma | 124 |
| Lymphoma, Non-Hodgkin | 109 |
| Inflammatory Bowel Diseases | 103 |
| Psoriasis | 103 |
Showing 5 of 314 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 78 |
| 2025 | 97 |
| 2024 | 100 |
| 2023 | 95 |
| 2022 | 83 |
| 2021 | 83 |
| 2020 | 94 |
| 2019 | 70 |
| 2018 | 62 |
| 2017 | 90 |
Showing 10 of 26 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 137 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 923 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (715)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| DEXAMETHASONE | Multiple Myeloma | Phase 3 | 19 |
| Etentamig | Multiple Myeloma | Phase 3 | 10 |
| DARATUMUMAB | Multiple Myeloma | Phase 3 | 8 |
| CARBOPLATIN | Lung Neoplasms | Phase 3 | 16 |
| Venetoclax | Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | 17 |
Showing 5 of 715 active programs.
Approved assets (156)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Venetoclax | 68 |
| ADALIMUMAB | 65 |
| Upadacitinib | 61 |
| Risankizumab | 60 |
| BOTULINUM TOXIN TYPE-A | 21 |
Showing 5 of 156 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 59% hit target (n=533) | 44% on time (n=504) |
Journals published in (365)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 54 |
| Blood | 46 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 39 |
| Annals of the rheumatic diseases | 29 |
| Lancet (London, England) | 27 |
Showing 5 of 365 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,057 | 91 | 2025-12-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 61,160,000,000 | 4,226,000,000 | 9,096,000,000 |
| 2024 | 56,334,000,000 | 4,278,000,000 | 12,791,000,000 |
| 2023 | 54,318,000,000 | 4,863,000,000 | 7,675,000,000 |
| 2022 | 58,054,000,000 | 11,836,000,000 | 6,510,000,000 |
| 2021 | 56,197,000,000 | 11,542,000,000 | 6,922,000,000 |
| 2020 | 45,804,000,000 | 4,616,000,000 | 6,379,000,000 |
| 2019 | 33,266,000,000 | 7,882,000,000 | 6,407,000,000 |
| 2018 | 32,753,000,000 | 5,687,000,000 | 10,329,000,000 |
| 2017 | 28,216,000,000 | 5,309,000,000 | 5,007,000,000 |
| 2016 | 25,638,000,000 | 5,953,000,000 | 4,385,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (39)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-08-04 | Debt financing | not disclosed | Sec extracted |
| 2026-03-04 | Debt financing | 8,000,000,000 | Sec extracted |
| 2026-02-26 | Debt financing | 7,991,337,500 | Edgar offerings |
| 2026-02-24 | Other financing | not disclosed | Edgar offerings |
| 2026-02-24 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 39 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 26 |
FDA recalls (20)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product of France, NDC 11980-174-10. | Class III | 2026-05-18 |
| Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230667043, | Class II | 2024-09-16 |
| Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230312042 | Class II | 2024-09-16 |
| Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, IL 60064, U.S.A. NDC 0074-7068-11 | Class III | 2023-10-17 |
| Ultane (sevoflurane), 250 mL, Inhalation Anesthetic, Rx only, Manufactured by: AbbVie Inc., North Chicago, IL 60064, USA. NDC 0074-4456-51 | Class III | 2018-01-22 |
Showing 5 of 20 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 7 | 2025-12-08 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| AbbVie Inc. | North Chicago, US | EMA, FDA, Health Canada | |
| AbbVie Ltd | Barceloneta, US | FDA | |
| AbbVie Ltd. | Cruce Davila, Barceloneta, US | Health Canada | |
| AbbVie Inc. | Wyandotte, US | FDA, Health Canada | |
| AbbVie Inc | North Chicago, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (276)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Roche (Switzerland) | Co sponsors trial with | 46 |
| Johnson & Johnson | Co sponsors trial with | 36 |
| Bristol Myers Squibb Co | Co sponsors trial with | 12 |
| Government of the United States of America | Co sponsors trial with | 10 |
| Dana-Farber Cancer Institute | Co sponsors trial with | 8 |
Showing 5 of 276 relationships.
Latest dated events (2,878)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,878 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| ABBVIE, LTD | Certificate of waiver | Active |
| ABBVIE, INC | Certificate of compliance | Terminated |
Biomarker capability evidence (2,771)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 2,771 evidence rows.
Biomarkers this organization publishes on (3)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: fda warning letters and fda untitled letters.